{"nctId":"NCT02186600","briefTitle":"Heartland Osteoporosis Prevention Study","startDateStruct":{"date":"2015-02-01","type":"ACTUAL"},"conditions":["Osteopenia"],"count":276,"armGroups":[{"label":"Control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Calcium Carbonate","Drug: Vitamin D3"]},{"label":"Risedronate","type":"EXPERIMENTAL","interventionNames":["Drug: Calcium Carbonate","Drug: Vitamin D3","Drug: Risedronate"]},{"label":"Exercise","type":"EXPERIMENTAL","interventionNames":["Drug: Calcium Carbonate","Drug: Vitamin D3","Behavioral: Bone-loading exercises"]}],"interventions":[{"name":"Calcium Carbonate","otherNames":["generic"]},{"name":"Vitamin D3","otherNames":["generic"]},{"name":"Risedronate","otherNames":["Actonel"]},{"name":"Bone-loading exercises","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women who are in their first 5 years of menopause\n* Have a T score between -1 and -2.49 at the femoral neck, total hip, or L1-L4 spine\n* Be 19 years of age or older\n* Have their health care provider's permission to enroll in the study.\n\nExclusion Criteria:\n\n* Have osteoporosis\n* Have a 10 yr probability of hip fracture \\>3% or major fracture \\>20% based on results of the fracture risk assessment (FRAX) tool\n* Currently take bisphosphonates, estrogen replacement therapy, glucocorticosteroids, or other drugs affecting bone\n* Currently participate in a resistance training or high impact weight bearing exercise program three or more times weekly\n* Weigh \\>300 lbs\n* Have abnormal results for the following laboratory tests: serum 25(OH)D; serum creatinine; serum calcium; parathyroid hormone (PTH); thyroid stimulating hormone (TSH).\n* Have Paget's disease, heart disease, uncontrolled hypertension, renal disease, or other concomitant conditions that prohibit participation in exercises, risedronate therapy, or use of CaD supplements.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Bone Strength Index of the Distal Tibia Based on Randomization to Control, Risedronate, or Exercise Group.","description":"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.\n\nBSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2098.7","spread":"334.7"},{"groupId":"OG001","value":"1993.3","spread":"292.3"},{"groupId":"OG002","value":"2001","spread":"332.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2105.89","spread":"322.822"},{"groupId":"OG001","value":"1997.32","spread":"307.103"},{"groupId":"OG002","value":"1987.42","spread":"300.136"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2107.2","spread":"326.4"},{"groupId":"OG001","value":"2014.2","spread":"306.7"},{"groupId":"OG002","value":"2009.2","spread":"280.4"}]}]}]},{"type":"SECONDARY","title":"Change in Bone Mineral Density (BMD) at the Spine (L1-L4) Based on Randomization to Control, Risedronate, or Exercise Group.","description":"Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.889","spread":"0.076"},{"groupId":"OG001","value":"0.892","spread":"0.06"},{"groupId":"OG002","value":"0.886","spread":"0.064"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".887","spread":".0755"},{"groupId":"OG001","value":".907","spread":".0666"},{"groupId":"OG002","value":".878","spread":".0619"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.885","spread":"0.070"},{"groupId":"OG001","value":"0.911","spread":"0.070"},{"groupId":"OG002","value":"0.885","spread":"0.065"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Measures of Bone Resorption (Serum NTx) Based on Randomization to Control, Risedronate, or Exercise Group.","description":"Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (\\~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.99","spread":"4.22"},{"groupId":"OG001","value":"14.31","spread":"4.44"},{"groupId":"OG002","value":"15.03","spread":"5.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.16","spread":"3.84"},{"groupId":"OG001","value":"10.30","spread":"3.93"},{"groupId":"OG002","value":"13.36","spread":"5.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.36","spread":"3.48"},{"groupId":"OG001","value":"11.42","spread":"4.71"},{"groupId":"OG002","value":"13.92","spread":"5.84"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":93},"commonTop":["Constipation","muscle or joint pain","Gi disturbances","Chest Pain or Dizziness"]}}}